New drug cuts down genetically inherited heart disease risk factor
(NewsNation) — An experimental drug has shown success in lowering the risk of genetically inherited heart disease by 94 percent during the second phase of its trial.
Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease, according to a press release Sunday.
'Nearly a quarter of the world's population has elevated levels of Lp(a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,' said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic.
'Unfortunately, there are no approved cholesterol-lowering therapies specifically for this genetic risk factor, and lifestyle changes like diet and exercise do not provide meaningful reductions,' Nissan added.
But, he continued, 'these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term dosing.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold 126 million rupees ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees.
Yahoo
3 hours ago
- Yahoo
Eli Lilly (LLY)'s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating
On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial. TD Cowen's analysis demonstrates that LLY's tirzepatide needs to match a MACE hazard ratio of 0.9 or better to statistically outperform dulaglutide. A scientist in a lab running tests on a variety of biopharmaceuticals. The investment firm hosted a survey of key opinion leaders, where 92% of the participants said they estimate a hazard ratio of 0.85 or better. Despite the positive outlook among survey respondents, investors remain wary about the possibility of attaining superiority over dulaglutide. Analysts also reworked their financial model for Eli Lilly and Company (NYSE:LLY) after the latest company updates and the Q1 2025 results. The 2026 EPS figures have been trimmed to $29.15, down by $0.25. The stock is now trading at a P/E ratio of 62.07, implying strong growth estimates. Eli Lilly and Company (NYSE:LLY) is a major global pharma giant based in Indianapolis that develops and commercializes medicines for diabetes, cancer, obesity, and autoimmune diseases. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
8 hours ago
- The Hill
1.7 million air conditioners recalled over reports of mold growth
(NewsNation) — About 1.7 million window air conditioning units have been recalled in the U.S. after 17 customers reported getting sick from fungal growth in the appliance. The Midea U and U+ window air conditioners may fail to drain quickly, causing mold growth that 'poses risks of respiratory issues or other infections to some consumers,' according to the U.S. Consumer Product Safety Commission. Nearly 46,000 units were also sold in Canada. There have been 152 reports of mold in the white AC units, including 17 reports of people saying exposure to the fungi made them cough, sneeze or have other allergic reactions. Units were sold under the brand names: The Midea air conditioners fit in windows and resonated with consumers because of their unique design, which allows consumers to close their windows 'through' the unit. The units were sold from March 2020 through May 2025 for $280 to $500 in-store and online at Costco, Menards, Best Buy, Home Depot and more. Customers who purchased the units can get a free repair or potentially a prorated refund by contacting Midea. Consumers who choose to use their air conditioners while awaiting a repair can go to to find out how to inspect their unit before continuing to use it. For more information, consumers can visit and click on 'Recall Information' or call (888) 345-0256 from 8 a.m. to 5 p.m. ET Mondays-Fridays. The Associated Press contributed to this report.
